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who used combination therapy (topical corticosteroid and TCI) (68%). Type of
health plan, Medicaid eligibility status, number of therapeutic class, comorbidity,
hospitalization or not andAD related costs during 12months before ADmedication
started were significantly associated with ADmedication adherence. Adherence to
AD medication was significantly negatively associated with total annual health-
care costs (p0.001) and with AD related costs (p0.001), adjusted for patient de-
mographic, comorbidity, and healthcare utilization characteristics before ADmedica-
tion started.CONCLUSIONS: Poor adherence to topical medication was observed in
pediatric AD, and adherence rates differed by the type and combination of AD
medication therapy. The detrimental effect of poor adherence on healthcare eco-
nomic outcome was significant, which implies a need to improve adherence in
order to reduce the financial impact of non-adherence. Factors which could con-
tribute non-adherence and financial burden need to be refined and targeted by
intervention to improve humanistic and economic outcomes of treatment.
PSS26
PATIENT’S EVALUATION OF THE QUICKNESS OF ACTION OF GINGIVAL
INFLAMMATION TREATMENTS
Mattout P1, Rahhali N2, Watt M3, Auges M2, Taieb C2
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OBJECTIVES: Gingivitis is defined as lesions on the gingival margin, expressed
through gum redness, bleeding, localized edema, and gingival sensitivity. It ismost
often caused by substances produced by bacterial plaque, or dental biofilm, which
develops along the gingival crevice.To evaluate, using patient’s interview results,
the quickness of action of several treatments for gingival inflammation.
METHODS:Observational, prospective, longitudinal,multicentric study carried out
in France, using data collected by participating dentists and dental surgeons.
RESULTS:A total of 316 patientswith gingivitis returned their questionnaire. wom-
en: 65.25%, current smokers:22.93% and 28.51% were ex-smokers. Light and heavy
bleeding during brushing was reported by 45.74% and 33.33% of patients respec-
tively. 45.70% reported visible redness, 56.34% reported swollen gums, 13.19% had
lesions, but above all 50.52% reported pain. Finally, 62.26% had previous history of
gingivitis symptoms. As for dental surgeons: 96.36% had performed scaling, 15.15%
gingival curettage, and 13.64% radicular resurfacing. A total of 78.4% judged gingi-
val inflammation to be moderate to severe, 63.10% said it had spread (30%). In
terms of treatment: 98.62% gave patients oral hygiene advice, 87.98% advised on
brushingmethods, 69.91% recommended specific toothpaste, and 78.85% amouth-
wash. A total of 30.61% had generalized inflammation after 1 month, reducing to
just 11.24% at 2months and 15.63% at 3months. A total of 88.08% reported improve-
ment in inflammation after the first month, 91.59% at 2 months and 93.59% at 3
months. A total of 83.93% felt less pain after 1 month of treatment, 87.90% after 2
months and 92.08% after 3 months.(p0.0418). 89.13% felt their treatment was effec-
tive after 1month, 97.79% after 2 months and 96.15% after 3 months.(p0.0036).
CONCLUSIONS: In terms of satisfaction, 86.52% were satisfied after 1 month, 94.85%
after 2months and 95.92% after 3months. (p0.0076). 87.57% felt their treatmentwas
easy to follow after 1month, 86.76% after 2months and 92.08% after 3months. Above
all, after the first month of treatment, 88.83% said they would continue using the
treatment in prevention even after complete disappearance of gingivitis.
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EFFECT OF TREATMENT SWITCH ON THE COST-EFFECTIVENESS OF BIOLOGICS
IN PSORIASIS IN PERU AND COLOMBIA
Alandete JC
Janssen-Cilag, Bogota, Colombia
OBJECTIVES: To evaluate the effect of treatment switch on the cost-effectiveness
of biologics used in patients with moderate or severe psoriasis in Colombia and
Perú. METHODS: In a previous study (Alandete, JC accepted in the ISPOR 13th
Anual European Congress) cost effectiveness of etanercept, adalimumab,
ustekinumab and infliximab was estimated based on label information for first-
(induction) year and second(maintenance) year assuming a 100% treatment
continuation ($1USDCOL$1.832SOL$2.75). For etanercept two induction
schemes were considered: 50mg weekly 52 weeks-D1- and 100mg 12 weeks fol-
lowed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in
Psoriasis Area and Severity Index-PASI 75- infliximab80%; ustekinumab69%;
adalimumab59%; etanerceptD2-52%; etanerceptD139%. Infliximab and
ustekinumab effectiveness were not significantly different. Both were significantly
superior to etanercept (Hawkins et al. meta-analysis presented in the 14th Interna-
tional ISPOR). In this abstract we developed a new model estimating switching
probabilities due to treatment failure atweek 12 and adverse events. Biologics costs
were adjusted considering time on the pre and post-switching periods. Treatment
effectiveness was adjusted when biologics were used after switching due to treat-
ment failure. RESULTS: Introduction of switching effect ratified ustekinumab dom-
inance in Colombia ($US44,675 in 2 years) generating cost savings of -$US4.049
versus etanerceptD1; -$US4.049 versus adalimumab; -$US7.844 versus etaner-
ceptD2 and -$US27.517 versus infliximab; with higher or same effectiveness than
the other biologics in that country. In Peru, ustekinumab changed from being the
most cost-effective option and became the dominant option ($US41.827 in 2 years)
generating cost savings of -$US283 versus etanerceptD1; -$US489 versus adali-
mumab; -$US3581 versus etanerceptD2 and -$US13.499 versus infliximab.
CONCLUSIONS: In the studied countries inclusion of the switching effect due to
treatment failure and adverse events ratifies cost-savings observed in Colombia
and makes ustekinumab the cost-saving option in Peru. These results corroborate
those observed in the USA and Europe.
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EFFECT OF DIFFERENT RECALL PERIODS ON DRY EYE SYMPTOM RATINGS
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OBJECTIVES: Clinical studies of dry eye disease (DED), a highly symptomatic dis-
ease, often ask patients to evaluate their DED symptoms using patient-reported
outcomes instruments. Most of these instruments use a one-week recall period.
The effect of this recall period on the accuracy of DED symptom assessments has
not been documented. The purpose of our research was to compare self-reported
DED symptoms between one-week and daily recall periods. METHODS: We en-
rolled 156 DED patients to a web-based observational study to assess their DED
symptoms once a day for 9 days. For each of the 14 symptoms, we asked the
patients to rate the frequency and intensity on a 0-6 rating scale, with a higher
score indicatingworse symptom. The assessments onDays 1 and 9 had a one-week
recall period, while the assessments on Days 2-8 had a one-day recall period. We
then calculated the mean weekly scores for Day 1 and Day 9 and the mean daily
scores for Days 2-8, and tested the differences between themean weekly and daily
scores using matched-pair t tests without multiplicity adjustment. RESULTS: The
Day 1mean weekly scores were significantly higher than themean daily scores for
all 14 symptoms in both frequency and intensity. The Day 1 mean weekly scores
were also significantly higher than the Day 9 mean weekly scores in 10 frequency
and 11 intensity scores. The Day 9 mean weekly scores were slightly higher than
the daily scores; however, most of the differences were not statistically significant.
CONCLUSIONS: Patients’ self-ratings of their DED symptoms using a one-week
recall period are consistently inflated when compared to their ratings using a one-
day recall period. Such inflation should be considered when designing clinical
studies for DED.
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DEVELOPMENT OF THE MODIFIED OCULAR COMFORT INDEX (MOCI)
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OBJECTIVES: Dry eye disease (DED) is characterized by symptoms of ocular dis-
comfort, visual disturbance and reduced tolerance to environmental stressors.
DED has a significant negative impact on the quality of life (QOL) of persons af-
fected, and imposes a massive burden on medical resources owing to its high
prevalence and chronic nature. It is not known if available patient-reported out-
come (PRO) instruments fully capture the scope of DED symptoms and their impact
on QOL. The purpose of our ongoing research is to develop a PRO instrument that
meets the needs of clinical studies investigating potential treatments for DED.
METHODS: Patients with DED in five countries (United States, United Kingdom,
Spain, Japan and Korea) were interviewed to identify their symptoms and the im-
pact of the disease on QOL (n120). Based on these results, itemswere drafted that
were tested in two web-based studies with mild-moderate DED subjects (n106
and 156) and face-to-face interviews with severe DED subjects (n22). RESULTS:
Items enquiring about 8 additional symptom experiences (16 items grouped in
doublets asking about frequency/intensity) were added to the original Ocular Com-
fort Index (OCI) using the same question format and response structure (fluctuat-
ing vision, light sensitivity, redness, foreign body sensation, excessive tearing, ex-
cessive blinking, ocular irritation and stickiness). Additionally, 2 items that
enquired about the most bothersome symptom and the extent of bother, and 12
items that appraised how symptoms interfered with the ability to perform daily
activities were included. CONCLUSIONS: Patient interviews suggest that available
PRO instruments do not fully capture the scope of DED symptoms and their impact
on QOL. The modified OCI (mOCI) will be used in clinical studies to facilitate its
refinement and validation.
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BURDEN OF INFANTILE HEMANGIOMA: DEVELOPMENT OF A QUESTIONNAIRE
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OBJECTIVES: Infantile hemangioma (IH) develops during the first weeks of life; it
normally forms within 3to6 months, then regresses very slowly over a duration of
3 to 7 years. In complicated forms, it is possible to encounter haemorrhaging,
necroses and ulcerations, infections and, more exceptionally, respiratory distress,
cardiovascular shunt. To explore the handicap, in its largest sense, generated by IH
using a questionnaire to express the burden on the daily life of the parents.
METHODS: The questionnaire was developed following a strict methodological
process, involving amultidisciplinary team incorporating various players (doctors,
nurses, social workers) who are involved in the treatment of patients or who are
specialised in the construction of questionnaires. A review of the literature and
discussions with the families were conducted in order to identify the concepts
related to the pathology. RESULTS: Exploratory assessments showed that the con-
cept of burden could be structured around two main modules: assess the impact
directly for the first-module. The consequences of HI on daily life, family and
personal relationships, work, financial situation and psychological impact for the
second-module. A third module focuses on the behaviour of the child; this module
will evolve over time and depending on the analyses. Fifty-six preliminary items
were identified following a first discussion. A first analysis managed to reduce
these items to 36 whilst conserving the 3 modules but making it easier to use the
analysis. CONCLUSIONS: The Hemangioma-Burden-Questionnaire will allow cli-
nicians to better understand the impact and consequences of the pathology on the
family. It will also allow the development of the burden to be monitored according
to the rate of development of the illness and its treatment.It will also allow the
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families of the children to better defend their interest before the health authorities
in terms of expenditure (medical or other) for which the part remaining their re-
sponsibility is increasing significantly.
Systemic Disorders/Conditions – Clinical Outcomes Studies
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SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED
WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA
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OBJECTIVES: Iron chelators (deferasirox or desferrioxamine) are essential to pa-
tients who need life-long blood transfusion (e.g. -Thalassemia). However, in 2010,
the US Food and Drug Administration (FDA) had issued a warning on potential
adverse events associatedwith iron chelators, especially deferasirox. The objective
of this retrospective cohort study was to compare the risk of renal impairment,
hepatic impairment, and gastrointestinal bleeding in patients with transfusion-
dependent anemia using deferasirox or desferrioxamine.METHODS: Patients with
transfusion-dependent anemia (sickle cell disease, -thalassaemia,myelodysplas-
tic syndrome and aplastic anemia) and were prescribed iron chelators (deferasirox
or desferrioxamine) were identified from the 20052009 Taiwan’s National Health
Insurance database. Cox proportional hazards models were used to assess the
association between iron chelators and occurrences of adverse events (renal im-
pairment, hepatic impairment, and gastrointestinal bleeding). All models adjusted
for age, sex, drug exposure (days), type of transfusion-dependent anemia andmed-
ical history. RESULTS: Patients were categorized into deferasirox (n180), desfer-
rioxamine (n586),and mixed users (n202), based on the drug they received dur-
ing the follow-up. The crude rates of adverse events were 4.14, 3.16 and 0.65 per
10,000 person-year in deferasirox, desferrioxamine and mix users, respectively.
After adjusting covariates, there was no association between deferasirox and ad-
verse events (hazard ratio [HR]0.84; 95% CI, 0.59–2.00) compared to desferrioxam-
ine users. CONCLUSIONS: In this population-based analysis, transfusion-depen-
dant anemia patients using deferasirox and desferrioxaminewere at similar risk of
adverse events.
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THE ASSOCIATION BETWEEN THERAPY WITH ANGIOTENSIN-CONVERTING
ENZYME INHIBITORS AND HEMOGLOBIN LEVEL
Chodick G1, Raz R1, Leshem E2, Steinvil A2, Berliner S2, Zeltser D2, Rogowski O2,
Shalev V1
1Maccabi Healthcare Services, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv,
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OBJECTIVES: To assess the hematological effects Angiotensin-converting enzyme
(ACE-I) inhibitors and Angiotensin II receptor blockers (ARB) in patients without
concomitant renal impairment. METHODS: In the present retrospective cohort
study we used the Maccabi Healthcare Services’ database to identify new users of
ACE-I (N14754) ARB (N751), or calcium channel blockers (CCB, N3087) with
available hemoglobin (Hb) tests between 2004 and 2009. Excluded were patients
purchasing drugs from more than one medication class, diagnosed with renal im-
pairment or cancer. Median Hb levels one year before and after first medication
purchase (index date)were calculated and compared according to the proportion of
days coveredwithmedication class. RESULTS: Persistent use of ACE-I and ARBwas
associated with a significant decrement in hemoglobin level. Patients at the high-
est PDC level were at a significantly higher risk of developing anemia among ACEI
(OR  1.59, p0.001), and ARB (OR  2.21, p0.05). The relationship between CCB
therapy andHb decrementwas substantially weaker. CONCLUSIONS:Hb levels are
reduced during the first year of ACE-I or ARB therapy. This association is dose-
dependent and is not likely to be caused by artifacts related to patient adherence.
PSY3
OPIOIDS IN NON-MALIGNANT PAIN: ARE THEY EQUIVALENT IN SAFETY
PROFILE? A NETWORK META-ANALYSIS
Siddiqui MK, Gupta J, Bhutani M, Sehgal M
Heron Health Private Ltd, Chandigarh, India
OBJECTIVES: Severe non-malignant pain affects a large number of patients. Opi-
oids are an important option for analgesia. However, there is relatively little infor-
mation about the comparative safety of opioids. We sought to compare the safety
and tolerability of commonly used opioids in non-malignant pain through network
meta-analyses of randomized controlled trials (RCTs). METHODS: Medline and
Embase were searched from 2000 to 2011 for RCTs comparing commonly used
opioids (tramadol, oxycodone, hydrocodone, propoxyphene, codeine) in non-ma-
lignant pain. Studies were assessed for inclusion/exclusion based on a prespecified
protocol. Two reviewers undertook data extraction independently. Any disagree-
ment was resolved by a third reviewer. A networkmeta-analysis was used to com-
bine direct and indirect evidence for safety outcomes reported in the trials. Based
on the incidence of adverse events (AEs) for each intervention, a probability-based
ranking (probability (P) of beingworst) was generated usingWinBUGS.RESULTS:Of
the 1156 studies, 5 RCTs enrolling 1399 patients were eligible for inclusion. The
most commonly reported AEs were nausea, vomiting, somnolence, dizziness,
headache, constipation and dry mouth. Withdrawals due to AEs were most com-
monly observedwith codeine (P42%) followed by hydrocodone (P28%), tramadol
(P19%), and oxycodone (P10%). The probability of occurrence of nausea and
somnolence was the highest with codeine. Dizziness was most frequently associ-
ated with oxycodone (P 53%). However, the incidence of dizziness and headache
was the lowest with codeine. Tramadol was observed to be associated with the
highest (P40%) incidence of vomiting, while hydrocodone had the lowest inci-
dence (P15%). CONCLUSIONS: Codeinewas observed to have the highest incidence
of withdrawals due to AEs. It was observed that the probability of occurrence of any
particular AE varied across included opioid analgesics. Codeine was observed to have
been more frequently associated with nausea/somnolence while tramadol and oxy-
codone had the highest incidence of vomiting and dizziness respectively.
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TRENDS IN HYPONATREMIA MANAGEMENT AND ASSOCIATED OUTCOMES IN
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OBJECTIVES: Although hyponatremia (HN) is the most common electrolyte abnor-
mality in hospitalized patients, little is known regarding the influence of HN and its
management on patient outcomes and healthcare resource usage. TheHNRegistry
is a novel prospective effort to document the clinical and healthcare outcomes of
HN and its management. Results for the first 25 HN patients enrolled are described
here.METHODS:After informed consent or waiver, data were extracted frommed-
ical charts of enrolled patients. HN was defined as a serum sodium  130 mmol/L.
The pilot data were summarized appropriately by sample size and for categorical
data by percentage. Subjects who had HN on admission were categorized as pre-
existing HN patients and those who were admitted for another reason and devel-
oped HN while in the hospital were categorized as hospital-acquired HN patients.
RESULTS: Overall, only 20% of the enrolled patients received any pharmacologic
management for HN and approximately 44% were discharged with persistent HN
(21% of treated vs. 79% of untreated). Among the patients discharged with HN, 55%
had a previous episode of HN. In addition, among the patients with previous HN,
46% were discharged with persistent HN. The length of stay for patients with pre-
existing HN was 1.3 days longer compared to patients with hospital-acquired HN.
These findings will be further evaluated and reported as more data in this large
registry study are accumulated. CONCLUSIONS:Amonghospitalized patients, HN is
frequently untreated, and nearly half of patients are discharged without normaliza-
tion of serum sodium. HN commonly persists through several hospital admissions.
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AN INVESTIGATION INTO THE RELATIONSHIP BETWEEN OBESITY AND SKIN
AND SOFT TISSUE INFECTIONS REQUIRING HOSPITALIZATION
Swiney J
University of Kentucky, Lexington, KY, USA
OBJECTIVES: The United States is experiencing an obesity epidemic with 67% of
adults being either overweight or obese. While it is known that excessive weight
increases the opportunity for skin infections, this relationship has not been well
studied. This study contributes to the knowledge about the relationship between
these two conditions.METHODS: Using the H-CUP national database for inpatient
hospitalizations, this study analyzed the data fromhospitals in the Southern states
for the number of skin and soft tissue infections in 2003, 2005 and 2007 in adults.
The proportion of patients who were also coded as obese in this population was
quantified. Two t-tests were performed comparing the average length of stay for
patients who were obese and not obese and the average total hospital charges for
patients who were obese and not obese. Two linear regressions analyzed the im-
pact of obesity on the cost of health care by using length of stay and total hospital
charges as dependent variables. RESULTS: The proportion of patients hospitalized
for skin and soft tissue infections who were also obese increased from 48.09% in
2003 to 51.7% in 2007. The average length of stay was 7.97 days for non-obese
patients verses 4.6 days for patients coded as obese which was statistically signif-
icant. The average total hospital charges were $26,653 for non-obese patients com-
pared to $20,876 for obese patients. This was also statistically significant. Surpris-
ingly, the co-morbidity of obesity has a negative predictive value for both hospital
length of stay and total hospital charges.CONCLUSIONS: It is possible that patients
who are obese are being discharged sooner because of differences in severity of
infections. More research is needed to determinewhether obesity is a causal factor
in skin and soft tissue infections and how this is affecting the cost and delivery of
health care.
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TRANSFUSIONAL IRON OVERLOAD (TIO) MONITORING AND TREATMENT:
FINDINGS FROM AN ELECTRONIC MEDICAL RECORDS REVIEW STUDY AT THE
MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
Duh MS1, Wetzstein G2, Guo A3, Sasane M3, Sarda SP1, Korves C1, Wang ST1, Wei R1,
Clinton B1, Ray L2
1Analysis Group, Inc., Boston, MA, USA, 2H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: We examined proportions of patients: a) monitored for TIO after
receiving 10, 20, and 30 units of red blood cells (RBC) and b) receiving iron
chelation therapy (ICT). We also examined overall survival (OS) among: a) moni-
tored vs. unmonitored; b) ICT-treated vs. ICT-untreated groups.METHODS: Medi-
cal records of patients 18 years receiving 10 RBC units 6 months before data
abstraction were identified at the Moffitt Cancer Center and Research Institute
(December 2009-June 2010). Observation period spanned from 10th RBC unit to end
of follow-up (i.e., death, clinic departure, or end of observation period). TIO moni-
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